A pharmacoepidemiological study of antiepileptic drug consumption (1992-2004);Estudio farmacoepidemiológico del consumo de fármacos antiepilépticos (1992-2004)

Revista de Neurologia

Volumn 46, Issue 8, 2008, Pages 449-453

  Abasolo Osinaga, Eider ^a   Abecia Inchaurregui, L C ^a   Etxeandia Ikobaltzeta, I ^a   Burgos Alonso, N ^a   Garcia del Pozo J ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antiepileptic drugs; Consumption; Defined daily doses per 1000 inhabitants per day; Epilepsy; Pharmacoepidemiological studies; Progress

Indexed keywords

ANTICONVULSIVE AGENT; BECLAMIDE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; METHYLPHENOBARBITAL; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SULTIAME; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VALPROMIDE; VIGABATRIN;

ANTICONVULSANT THERAPY; ARTICLE; DATA BASE; DRUG USE; EPILEPSY; HUMAN; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; SPAIN;

EID: 44449114610     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4608.2008020     Document Type: Article

References (49)

1. Tejeiro-Martínez J, Barcenilla-Rodríguez B. Epidemiología de la epilepsia. Rev Neurol Clin 2000; 1: 229-45.
2. Martínez-Bermejo A. Principios básicos para estudios epidemiológicos en epilepsia. Rev Neurol 2002; 34: 519-26.
3. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Chemical Classification Index with defined daily doses (DDD's). Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2003.
4. Laporte JR, Tognoni G. Estudios de utilización de medicamentos y de farmacovigilancia. In Laporte JR, Tognoni G. Principios de epidemiología del medicamento. Barcelona: Masson-Salvat; 1993. p. 1-24.
5. Bharucha NE, Bharucha EP, Bharucha AE, Bhise AV, Schoenberg BS. Prevalence of epilepsy in the Parsi community of Bombay. Epilepsia 1988; 29: 111-5.
6. Zielinski JJ. Epileptics not in treatment. Epilepsia 1974; 15: 203-10.
7. Banfi R, Borselli G, Mariani C, Borgheresi A, Cavalieri A. Epidemiological study of epilepsy by monitoring prescriptions of antiepileptic drugs. Pharm World Sci 1995; 17: 138-40.
8. Beghi E, Monticelli ML, Monza G, Sessa A, Zarrelli M. Antiepileptic drugs as 'tracers' of disease. Neuroepidemiology 1991; 10: 33-41.
9. Zolo P, Bianchi A, Tiezzi A. Epidemiology of epilepsy by means of the analysis of drug prescription. Boll Lega Ital Epilessia 1986; 54-55: 345-7.
10. Giuliani G, Terziani S, Senigaglia AR, Luccioni G, Foschi N, Maffei C. Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. Acta Neurol Scand 1992; 85: 23-31.
11. Maremmani C, Rossi G, Bonucclli U, Murri L. Descriptive epidemiologic study of epilepsy syndromes in a district of northwest Tuscany, Italy. Epilepsia 1991; 32: 294-8.
12. Placencia M, Shorvon SD, Paredes JV, Bimos C, Sander JWAS, Cascante SM. Epileptic seizures in an Andean region of Ecuador: incidence and prevalence and regional variation. Brain 1992; 115: 771-82.
13. Gómez JG, Arciniegas E, Torres J. Prevalence of epilepsy in Bogotá, Colombia. Neurology 1978; 28: 90-5.
14. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975; 16: 1-66.
15. Gudmundsson G. Epilepsy in Iceland. Acta Neurol Scand 1966; 43: 5-25.
16. Aziz H, Ali SM, Frances P, Khan MI, Hasan RZ. Epilepsy in Pakistan: a population-based epidemiological study. Epilepsia 1994; 35: 950-8.
17. Britten N, Morgan K, Fenwick PBC, Britten H. Epilepsy and handicap from birth to age 36. Dev Med Child Neurol 1986; 28: 719-28.
18. Wajsbort J, Haral N, Alfandary I. A study of the epidemiology of chronic epilepsy in Northern Israel. Epilepsia 1967; 8: 105-16.
19. Oller-Daurella L, Oller FVL, Laguinas MA, Carol A, Russi A, Sánchez ME. Banco de datos de epilepsia: ejemplo práctico de informática médica. Revisión de una casuística global de 3.000 epilépticos. An Med Intern 1986; 3: 72-5.
20. Sander JW The incidence and prevalence of epilepsy. In: The National Society for Epilepsy 2003. URL: http://www.e-epilepsy.org.uk/pages/articles/ show_article.cfm?id=26#. [14.03.2008].
21. Leviton A, Cowan LD. Epidemiology of seizure disorders in children. Neuroepidemiology 1982; 1: 40-83.
22. Levy J. Epilepsy in Rhodesia, Zambia and Malawi. Afr J Med Sci 1970; 1: 291-303.
23. Van der Waals FW, Goudsmit J, Gajdusek DC. Clinical characteristics of highly prevalent seizure disorders in the Gbawein and Wroughbarch clan region, Graan Bassa Country, Liberia. Neuroepidemiology 1983; 23: 364-73.
24. Jilek-Aall L, Jilek W, Miller JR. Clinical and genetic aspects of seizure disorders prevalent in an isolated African population. Epilepsia 1979; 20: 613-22.
25. Scambler G, Hopkins A. Social class, epileptic activity, and disadvantage at work. J Epidemiol Community Health 1980; 34: 129-33.
26. Basch EM, Cruz ME, Tapia D, Cruz A. Prevalence of epilepsy in a migrant population near Quito, Ecuador. Neuroepidemiology 1997; 16: 94-8.
27. Lavados J, Germain L, Morales A, Campero M, Lavados P. A descriptive study of epilepsy in the district of El Salvador, Chile. Acta Neurol Scand 1992; 85: 249-53.
28. National Health Survey. Prevalence of chronic conditions in the United States. Series 10, no. 109. Washington: DHEW; 1973.
29. Heaney DC, MacDonald BK, Everitt A, Stevenson S, Leonardi GS, Wilkinson P. Socioeconomic variation in incidence of epilepsy: prospective community based study in south east England. Br J Med 2002; 325: 1013-16.
30. Commission on Epidemiology and Prognosis of the International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993; 34: 592-6.
31. De Pedro-Cuesta J, Cuadrado JI. Evaluación epidemiológica de consumo de levodopa. Rev Neurol 2000; 31: 1028-30.
32. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58: 2-8.
33. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003; 2: 473-81.
34. Gil-Nagel A. Review of new antiepileptic drugs as initial therapy. Epilepsia 2003; 44: 3-10.
35. LaRoche SM, Helmers SL. The new antiepileptic drugs. JAMA 2004; 291: 605-14.
36. Steinhoff BJ, Hirsch E, Mutani R, Nakken KO. The ideal characteristics of antiepileptic therapy: an overview of old and new AEDs. Acta Neurol Scand 2003; 107: 87-95.
37. Deckers CI, Knoester PD, De Haan GJ, Keyser A, Renier WO, Hekster YA. Selection criteria for the clinical use of the newer antiepileptic drugs. CNS Drugs 2003; 17: 405-21.
38. Bejín AM, Connolly M. New antiepileptic drug therapies. Neurol Clin N Am 2002; 1163-82.
39. Campos-Olazábal P. Riesgos y beneficios de los nuevos fármacos antiepilépticos. Rev Neurol 2006; 42 (Supl 1): S57-60.
40. González-Suárez D, Sardinas-Hernández N, Asencio-Guerra AJ. Tratamiento farmacológico y régimen de empleo en epilepsia. Rev Neurol 1999; 29: 714-8.
41. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology 2004; 62: 1252-60.
42. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Neurology 2004; 62: 1261-73.
43. Forsgren I, Beghi E, Ekman M. Cost of epilepsy in Europe. Eur J Neurol 2005; 12: 54-8.
44. Arroyo S, Fossas P, Nieto-Barrera M, Salas-Puig X, Sánchez- Álvarez JC, Serratosa JM, et al. Análisis de coste- minimización del tratamiento antiepiléptico en monoterapia en pacientes con epilepsia de reciente diagnóstico: situación en España. Rev Neurol 2000; 31: 828-32.
45. Mesa T, Mesa JT, Guarda J, Mahaluf F, Pauchard F, Undurraga E, et al. Costes directos de la epilepsia en una población chilena. Rev Neurol 2007; 44: 710-4.
46. Díaz S, Argumosa A, Horga JF, Vera M, Dukes E, Rejas J. Análisis coste-efectividad del tratamiento de la epilepsia parcial refractaria: un modelo de simulación de pregabalina y levetiracetam. Rev Neurol 2007; 45: 460-7.
47. Saiz-Díaz RA. Antiepilépticos: aportación de los nuevos fármacos. Inf Ter Sist Nac Salud 2004; 28: 33-40.
48. Rubio M, Lizán L, Badia X, Escartín-Siquier AE, López-Trigo J, Rufo-Campos M, et al. Análisis de minimización de costes del tratamiento farmacológico antiepiléptico en España. Rev Neurol 2006; 42: 257-64.
49. Sancho J. Características e indicaciones de la gabapentina. Rev Neurol 2002; 35: 85-7.